For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration agreement revenue | 0 | 0 | - | 18,333.333 |
| Research and development | 936,000 | 1,368,000 | 1,530,000 | 1,328,000 |
| Selling, general and administrative | 552,000 | 683,000 | 1,196,000 | 997,500 |
| Total costs and expenses | 1,488,000 | 2,051,000 | 2,726,000 | 2,325,500 |
| Operating loss | -1,488,000 | -2,051,000 | -2,726,000 | -2,298,000 |
| Total other income, net | 5,000 | 2,000 | 14,000 | 16,500 |
| Net loss | -1,483,000 | -2,049,000 | -2,712,000 | -2,281,500 |
| Net loss per share, basic and diluted (in dollars per share) | -0.24 | -0.4 | -0.59 | -0.705 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 6,277,848 | 5,059,736 | 4,635,764 | -980,366.5 |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)